子宫移植受者剖宫产术后新发剖宫产瘢痕憩室
本研究为回顾性先导性病例系列,纳入两个子宫移植中心的19例经移植子宫剖宫产且有意再孕的受者,评估产后经阴道超声发现的剖宫产瘢痕憩室(峡部憩室)。6/19例(31.6%)出现憩室,平均分娩孕周35 4/7周,未见既往产科并发症与憩室形成的关联。结论认为移植子宫的剖宫产瘢痕愈合可能未因免疫抑制而明显受损。
要点
- 19例移植子宫剖宫产受者中6例(31.6%)超声发现峡部憩室。
- 平均分娩孕周为35 4/7周。
- 小样本中既往产科并发症与憩室形成无关联。
核心结论
- 移植子宫受者的峡部憩室发生率与非移植人群相当,提示免疫抑制治疗可能未显著影响剖宫产瘢痕愈合。
- 识别该人群的峡部憩室具有临床意义,可能指导供体子宫特征选择并影响子宫移植的生育治疗。
研究设计与样本
- 回顾性先导研究,附代表性病例系列。
- 来自两个三级保健子宫移植中心,覆盖全球近半数子宫移植病例。
- 纳入19例使用移植子宫至少完成1次剖宫产、有意再次妊娠且有产后经阴道超声影像的受者。
主要发现
- 19例中6例(31.6%)经阴道超声显示与峡部憩室一致的影像学表现。
- 平均分娩孕周为35 4/7周。
- 在该小样本队列中,未发现既往产科并发症与后续峡部憩室形成之间的关联。
- 在受累患者中,66.7%接受的是供体在捐献前曾行剖宫产的子宫。
关键数值与推荐
- 峡部憩室定义为既往子宫切口部位的楔形肌层缺损。
- 主要结局为产后经阴道超声检出峡部憩室。
- 6/19例(31.6%)检出峡部憩室。
- 平均分娩孕周35 4/7周。
- 受累患者中66.7%的供体子宫在捐献前有剖宫产史。
临床怎么用
- 对子宫移植受者剖宫产后应常规行影像学监测以识别峡部憩室。
- 发现憩室后需在再次妊娠的高风险生育治疗中综合评估与管理。
- 供体子宫是否曾有剖宫产史可作为移植供体评估的参考信息。
局限性
- 回顾性先导研究,样本量小(19例)。
- 未识别出与憩室形成相关的危险因素。
- 作者指出需更大规模前瞻性研究进一步明确危险因素并优化手术与生殖结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY OBJECTIVE: To determine the incidence of cesarean scar defect (isthmocele) formation for uterus transplant (UTx) recipients in the setting of immunosuppression and required cesarean deliveries. DESIGN: Retrospective pilot study with illustrative case series. SETTING: Two tertiary-care uterus transplantation programs representing nearly half of uterus transplant cases worldwide. PATIENTS: Nineteen UTx recipients who underwent at least 1 cesarean delivery using their transplanted uterus, who desired a second pregnancy, and who had postpartum transvaginal ultrasound imaging available. INTERVENTIONS: Uterus transplantation followed by embryo transfer and planned cesarean delivery, with routine postoperative imaging surveillance. MEASUREMENTS AND MAIN RESULTS: The primary outcome was the presence of a postpartum isthmocele on transvaginal ultrasound, defined as a wedge-shaped myometrial defect at the site of an earlier hysterotomy. Six of 19 patients (31.6%) showed imaging findings consistent with an isthmocele. The mean gestational age at delivery was 35 4/7 weeks. No association was identified between earlier obstetric complications and subsequent isthmocele formation in our small cohort. Among affected patients, 66.7% received donor uteri with cesarean delivery before donation. Representative cases highlight a clinical spectrum of presentations in this context and illustrate the underlying clinical complexity when isthmocele is encountered during a high-stakes fertility journey. CONCLUSION: UTx recipients in our cohort showed isthmocele formation comparable with that reported in non-transplant populations. These findings suggest that cesarean scar healing may not be significantly impaired in the transplanted uterus even despite exposure to immunosuppressive therapy. Recognition of isthmocele in this population is clinically relevant, as it may guide transplant donor characteristics and impact UTx fertility treatment. Larger prospective studies are warranted to further define risk factors and optimize surgical and reproductive outcomes.
引用
- Yazdani A, Kuznicki M, Testa G, et al. De Novo Isthmocele Formation After Cesarean Delivery in Uterus Transplant Recipients. J Minim Invasive Gynecol. 2026. PMID: 42392354. doi:10.1016/j.jmig.2026.06.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。